All AbMole products are for research use only, cannot be used for human consumption.
BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM.
Cell Death Discov. 2023 Jun 30;9(1):205.
RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma
BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) purchased from AbMole
J Cancer Res Clin Oncol. 2023 Feb 6.
Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS–STING pathway
BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) purchased from AbMole
J Allergy Clin Immunol. 2020 Mar;145(3):855-867.e8.
Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis.
BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) purchased from AbMole
| Molecular Weight | 475.58 |
| Formula | C29H33NO5 |
| CAS Number | 1675201-83-8 |
| Solubility (25°C) | DMSO: ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Tsukahara T, et al. Expert Opin Biol Ther. The future of immunotherapy for sarcoma.
| Related PD-1/PD-L1 Products |
|---|
| PD-1/PD-L1-IN-9
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model. |
| NSC622608
NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM. |
| PD-L1-IN-1
PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. |
| SL-279252
SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours. |
| Rosnilimab
Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
